Navigation Links
Non-IV-administered medication just as effective in stopping seizures

CINCINNATIWhen seizures strike, the most immediate goal for caregivers is to get appropriate medication to the patient as quickly as possible to stop the seizing activity.

In a paper published in the June Academic Emergency Medicine, UC emergency medicine assistant professor Jason McMullan, MD, found that the best means of stopping status epilepticus (SE) may be with the least direct medication.

In the meta-analysis, McMullan compiled the results of six studies featuring 774 patients. His analysis compared the efficacy of two seizure medications, diazepam and non-intravenous midazolam, in stopping SE in children and young adults.

Both medications are in a class of drugs called benzodiapines, with diazepam the more commonly used anti-seizure drug in pre-hospital settings. While diazepam is typically administered by either suppository or IV, midazolam can be administered by a shot in the muscle or intranasally.

In the minutes after a seizure, the method of administration can make a big difference, says McMullan.

"Establishing IV access can be challenging, if not impossible, in convulsing patients," he says. While an intravenous medication may access the bloodstream faster, it can take a long time before the patient actually gets the medicine.

"Suppositories present another challenge," adds McMullan, because some caregivers may be unwilling to administer a suppository to a seizing child in a public place.

"It may be a little bit slower for midazolam administered via shot or nasal spray to work," he says, "but when you factor in the time to start the IV or administer a suppository, then it becomes a lot quicker."

During a seizure, time saved often translates into a better outcome for the patient.

"Most seizures stop on their own, but there times that they don'tand when they don't, that's a true emergency," says McMullan. "If a person is seizing for five or more minutes, the chances of the seizure stopping on its own are far less. During that time the person can suffer brain damage, muscle damage, a lack of oxygen, kidney damage, any number of things. The sooner that person is treated, the better they're going to do and the less medicine that they need."

In the analysis, McMullan found that midazolam, administered by any route, was superior to diazepam for stopping seizures, by any route. Not only was midazolam administered faster that diazepam, it had no greater rate of respiratory side effects.

While McMullan cautions that further studies including adult patients and comparing other anti-seizure medications are needed, he is optimistic about what this means for advancing the standard of care in seizures.

"In broad strokes, these results mean midazolam could be a good idea for seizure treatment. It's no worse than the gold standard of putting the drug directly into the bloodstream, it's no more dangerous and it's quicker. The real promise if that it may open the possibility for more EMS agencies to use this medication."


Contact: Katy Cosse
University of Cincinnati Academic Health Center

Related medicine news :

1. PharmMD Secures Investments to Fund New Opportunities in Medication Therapy Management
2. Northeast Chiropractic, PC Revolutionizes Pain Management Without Medication, Now Offering New and Unique Blend of Treatments
3. Pharmacists Encourage Consumers to Practice Safe Medication Storage and Disposal
4. Anti-spasticity medications need further research
5. Study highlights lack of patient knowledge regarding hospital medications
6. Pathological Gambling May Be Successfully Treated With Medications for Substance Addiction
7. Medicine-On-Time Partners With QuickMAR to Streamline Medication Management and Improve Patient Care
8. Herpes medication does not reduce risk of HIV transmission, UW-led international study finds
9. A novel computational model -- how Parkinsons medications affect learning and attention
10. First Oral Medications For MS Show Promise
11. Racial differences in medication use
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology: